Am J Psychiatry 163:2096-2102, December 2006
doi: 10.1176/appi.ajp.163.12.2096
© 2006 American Psychiatric Association
Randomized Comparison of Olanzapine Versus Risperidone for the Treatment of First-Episode Schizophrenia: 4-Month Outcomes
Delbert G. Robinson, M.D.,
Margaret G. Woerner, Ph.D.,
Barbara Napolitano, M.A.,
Raman C. Patel, M.D.,
Serge M. Sevy, M.D., M.B.A.,
Handan Gunduz-Bruce, M.D.,
Jose M. Soto-Perello, M.D.,
Alan Mendelowitz, M.D.,
Ali Khadivi, Ph.D.,
Rachel Miller, L.C.S.W.,
Joanne McCormack, L.C.S.W.,
Beth S. Lorell, L.C.S.W.,
Martin L. Lesser, Ph.D.,
Nina R. Schooler, Ph.D., and
John M. Kane, M.D.
OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders. METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5–20 mg/day) or risperidone (1–6 mg/day). RESULTS: Response rates did not significantly differ between olanzapine (43.7%, 95% CI=28.8%–58.6%) and risperidone (54.3%, 95% CI=39.9%–68.7%). Among those responding to treatment, more subjects in the olanzapine group (40.9%, 95% CI=16.8%–65.0%) than in the risperidone group (18.9%, 95% CI=0%–39.2%) had subsequent ratings not meeting response criteria. Negative symptom outcomes and measures of parkinsonism and akathisia did not differ between medications. Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2–1.6) with risperidone and 1.2 (95% CI=1.0–1.4) with olanzapine. Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%–20.5%) with olanzapine and 11.3% (95% CI=8.4%–14.3%) with risperidone. Body mass index at baseline and at 4 months was 24.3 (95% CI=22.8–25.7) versus 28.2 (95% CI=26.7–29.7) with olanzapine and 23.9 (95% CI=22.5–25.3) versus 26.7 (95% CI=25.2–28.2) with risperidone. CONCLUSIONS: Clinical outcomes with risperidone were equal to those with olanzapine, and response may be more stable. Olanzapine may have an advantage for motor side effects. Both medications caused substantial rapid weight gain, but weight gain was greater with olanzapine.
This article has been cited by other articles:
|
|
|
|
 
M. Alvarez-Jimenez, A. G. Parker, S. E. Hetrick, P. D. McGorry, and J. F. Gleeson
Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis
Schizophr Bull,
November 9, 2009;
(2009)
sbp129v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. U. Correll, P. Manu, V. Olshanskiy, B. Napolitano, J. M. Kane, and A. K. Malhotra
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA,
October 28, 2009;
302(16):
1765 - 1773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Jensen
Drug-Induced Hyperphagia: What Can We Learn From Psychiatric Medications?
JPEN J Parenter Enteral Nutr,
September 1, 2008;
32(5):
578 - 581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Bibliography Schizophrenia
Focus,
April 1, 2008;
6(2):
197 - 199.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Goldberg, R. S. Goldman, K. E. Burdick, A. K. Malhotra, T. Lencz, R. C. Patel, M. G. Woerner, N. R. Schooler, J. M. Kane, and D. G. Robinson
Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode Schizophrenia: Is It a Practice Effect?
Arch Gen Psychiatry,
October 1, 2007;
64(10):
1115 - 1122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Et al
Evid. Based Ment. Health,
August 1, 2007;
10(3):
71 - 72.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2006
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
